Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia

Calcineurin (CN), a calcium- and calmodulin-dependent protein phosphatase, plays a significant role in the central nervous system. Previously, we reported that forebrain-specific CN knockout mice (CN mutant mice) have impaired working memory. To further analyze the behavioral effects of CN deficiency, we subjected CN mutant mice to a comprehensive behavioral test battery. Mutant mice showed increased locomotor activity, decreased social interaction, and impairments in prepulse inhibition and latent inhibition. In addition, CN mutant mice displayed an increased response to the locomotor stimulating effects of MK-801. Collectively, the abnormalities of CN mutant mice are strikingly similar to those described for schizophrenia. We propose that alterations affecting CN signaling could comprise a contributing factor in schizophrenia pathogenesis.

[1]  Susumu Tonegawa,et al.  Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Egan,et al.  Pharmacological Agents That Directly Modulate Insulin Secretion , 2003, Pharmacological Reviews.

[3]  J. Coyle,et al.  Glutamatergic mechanisms in schizophrenia. , 2003, Annual review of pharmacology and toxicology.

[4]  V. Arolt,et al.  The Influence of Typical and Atypical Neuroleptic Drugs in the Production of Interleukin-2 and Interferon-Gamma in vitro , 2003, Neuropsychobiology.

[5]  Petri Törönen,et al.  Antipsychotic drug treatment induces differential gene expression in the rat cortex , 2002, Journal of neurochemistry.

[6]  M. Davidson.  Risk of cardiovascular disease and sudden death in schizophrenia. , 2002, The Journal of clinical psychiatry.

[7]  J. Kemp,et al.  Severe Impairment of NMDA Receptor Function in Mice Carrying Targeted Point Mutations in the Glycine Binding Site Results in Drug-Resistant Nonhabituating Hyperactivity , 2002, The Journal of Neuroscience.

[8]  S. Seidman.  Exploring the relationship between depression and erectile dysfunction in aging men. , 2002, The Journal of clinical psychiatry.

[9]  D. Henderson,et al.  Schizophrenia and diabetes. , 2002, International review of neurobiology.

[10]  R. Yolken,et al.  The Schizophrenia–Rheumatoid Arthritis Connection: Infectious, Immune, or Both? , 2001, Brain, Behavior, and Immunity.

[11]  T. Pollmächer,et al.  In Vitro Cytokine Secretion in Individuals with Schizophrenia: Results, Confounding Factors, and Implications for Further Research , 2001, Brain, Behavior, and Immunity.

[12]  T. Bayer,et al.  Review of Immunological and Immunopathological Findings in Schizophrenia , 2001, Brain, Behavior, and Immunity.

[13]  Hongkui Zeng,et al.  Forebrain-Specific Calcineurin Knockout Selectively Impairs Bidirectional Synaptic Plasticity and Working/Episodic-like Memory , 2001, Cell.

[14]  P. Robinson,et al.  The dephosphins: dephosphorylation by calcineurin triggers synaptic vesicle endocytosis , 2001, Trends in Neurosciences.

[15]  R. Gainetdinov,et al.  Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Wess,et al.  Hyperactivity and Intact Hippocampus-Dependent Learning in Mice Lacking the M1 Muscarinic Acetylcholine Receptor , 2001, The Journal of Neuroscience.

[17]  J. David Sweatt,et al.  Roles of serine/threonine phosphatases in hippocampel synaptic plasticity , 2001, Nature Reviews Neuroscience.

[18]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Crabtree.  Calcium, Calcineurin, and the Control of Transcription* , 2001, The Journal of Biological Chemistry.

[20]  A Carlsson,et al.  Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. , 2001, Annual review of pharmacology and toxicology.

[21]  M. Picciotto,et al.  Fear conditioning and latent inhibition in mice lacking the high affinity subclass of nicotinic acetylcholine receptors in the brain , 2000, Neuropharmacology.

[22]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[23]  W. Bechstein,et al.  Neurotoxicity of calcineurin inhibitors: impact and clinical management , 2000, Transplant international : official journal of the European Society for Organ Transplantation.

[24]  Daniel R Weinberger,et al.  To Model a Psychiatric Disorder in Animals: Schizophrenia As a Reality Test , 2000, Neuropsychopharmacology.

[25]  R. V. Van Heertum,et al.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. Olson,et al.  Calcineurin Signaling and Muscle Remodeling , 2000, Cell.

[27]  B. Lipska,et al.  Exaggerated MK‐801‐induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus , 2000, Behavioural pharmacology.

[28]  Jacqueline N. Crawley,et al.  What's Wrong With My Mouse?: Behavioral Phenotyping of Transgenic and Knockout Mice , 2000 .

[29]  P. Mertz,et al.  Calcineurin: form and function. , 2000, Physiological reviews.

[30]  T. Goldberg,et al.  Cognitive impairment in schizophrenia is the core of the disorder. , 2000, Critical reviews in neurobiology.

[31]  P. De Camilli,et al.  The Calcineurin-Dynamin 1 Complex as a Calcium Sensor for Synaptic Vesicle Endocytosis* , 1999, The Journal of Biological Chemistry.

[32]  Marc G Caron,et al.  Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.

[33]  P. Greengard,et al.  Beyond the Dopamine Receptor: Review the DARPP-32/Protein Phosphatase-1 Cascade , 1999 .

[34]  J. Crawley.  Behavioral Phenotyping of Transgenic and Knockout Mice , 1999 .

[35]  P. Tugwell,et al.  US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. , 1999, The Journal of rheumatology.

[36]  S. Snyder,et al.  Neural actions of immunophilin ligands. , 1998, Trends in pharmacological sciences.

[37]  Richard Paylor,et al.  Social Interaction and Sensorimotor Gating Abnormalities in Mice Lacking Dvl1 , 1997, Cell.

[38]  J. Yakel.  Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. , 1997, Trends in pharmacological sciences.

[39]  A Carlsson,et al.  Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. , 1997, Life sciences.

[40]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[43]  P. Goldman-Rakic.  Working memory dysfunction in schizophrenia. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[44]  R. Hales,et al.  J Neuropsychiatry Clin Neurosci , 1992 .

[45]  J. Craven.  Cyclosporine-associated organic mental disorders in liver transplant recipients. , 1991, Psychosomatics.

[46]  D L Braff,et al.  Sensorimotor gating and schizophrenia. Human and animal model studies. , 1990, Archives of general psychiatry.

[47]  G. Forbes,et al.  Central Nervous System Toxicity after Liver Transplantation , 1987 .

[48]  D. Weinberger.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[49]  S. Barnett.  Psychosomatics , 1973, Nature.

[50]  B. Pitt.  Psychopharmacology , 1968, Mental Health.

[51]  Burton S. Rosner,et al.  Neuropharmacology , 1958, Nature.